弥漫性大 B 细胞淋巴瘤：2012 年，我们如何治愈更多患者？
Diffuse large B cell lymphoma: how can we cure more patients in 2012?
机构信息
Division of Hematologic Oncology, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, United States.
出版信息
Best Pract Res Clin Haematol. 2012 Mar;25(1):41-7. doi: 10.1016/j.beha.2012.01.008. Epub 2012 Feb 24.
PMID:22409822
Abstract
Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.
摘要
从临床角度来看，本章将重点关注 2012 年弥漫性大 B 细胞淋巴瘤（DLBCL）治疗中 3 个重要问题：风险分层、中期 PET-CT 扫描以及复发和原发耐药患者接受利妥昔单抗时代大剂量化疗和 ASCT 的作用。
相似文献
1
Diffuse large B cell lymphoma: how can we cure more patients in 2012?
Best Pract Res Clin Haematol. 2012 Mar;25(1):41-7. doi: 10.1016/j.beha.2012.01.008. Epub 2012 Feb 24.
2
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.
3
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8.
4
Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.
5
Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.
Br J Haematol. 2013 Mar;160(5):608-17. doi: 10.1111/bjh.12176. Epub 2012 Dec 29.
6
A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
Ann Hematol. 2011 Feb;90(2):185-92. doi: 10.1007/s00277-010-1060-8. Epub 2010 Sep 1.
7
The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Am J Clin Pathol. 2011 Jan;135(1):54-61. doi: 10.1309/AJCPJX4BJV9NLQHY.
8
Improving outcomes for patients with diffuse large B-cell lymphoma.
CA Cancer J Clin. 2010 Nov-Dec;60(6):393-408. doi: 10.3322/caac.20087. Epub 2010 Oct 28.
9
Relapses, treatments and new drugs.
Best Pract Res Clin Haematol. 2012 Mar;25(1):49-60. doi: 10.1016/j.beha.2012.01.002. Epub 2012 Feb 4.
10
Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Oncol Rep. 2011 Apr;25(4):1183-90. doi: 10.3892/or.2011.1179. Epub 2011 Feb 10.
引用本文的文献
1
LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma.
J Clin Lab Anal. 2022 Oct;36(10):e24680. doi: 10.1002/jcla.24680. Epub 2022 Sep 4.
2
Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.
Cureus. 2021 Feb 4;13(2):e13120. doi: 10.7759/cureus.13120.
3
BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma.
Oncol Lett. 2017 Sep;14(3):3767-3773. doi: 10.3892/ol.2017.6577. Epub 2017 Jul 15.
4
A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Oncotarget. 2016 Jul 5;7(27):41242-41250. doi: 10.18632/oncotarget.9271.
5
Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.
PLoS One. 2014 Sep 25;9(9):e106745. doi: 10.1371/journal.pone.0106745. eCollection 2014.
6
Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP.
Cancer Sci. 2013 Sep;104(9):1245-51. doi: 10.1111/cas.12215. Epub 2013 Jul 11.
7
FDG PET/CT in children and adolescents with lymphoma.
Pediatr Radiol. 2013 Apr;43(4):406-17. doi: 10.1007/s00247-012-2559-z. Epub 2013 Mar 24.
8
Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.
PLoS One. 2012;7(7):e41658. doi: 10.1371/journal.pone.0041658. Epub 2012 Jul 23.
Zotero 插件